Cargando…

Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice

Equitable access to vaccines is necessary to limit the global impact of the coronavirus disease 2019 (COVID-19) pandemic and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. In previous studies, we described the development of a low-cost vaccine based on a...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Domínguez, Irene, Martínez, Jose Luis, Slamanig, Stefan, Lemus, Nicholas, Liu, Yonghong, Lai, Tsoi Ying, Carreño, Juan Manuel, Singh, Gagandeep, Schotsaert, Michael, Mena, Ignacio, McCroskery, Stephen, Coughlan, Lynda, Krammer, Florian, García-Sastre, Adolfo, Palese, Peter, Sun, Weina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241906/
https://www.ncbi.nlm.nih.gov/pubmed/35658571
http://dx.doi.org/10.1128/spectrum.01538-22
_version_ 1784737928785690624
author González-Domínguez, Irene
Martínez, Jose Luis
Slamanig, Stefan
Lemus, Nicholas
Liu, Yonghong
Lai, Tsoi Ying
Carreño, Juan Manuel
Singh, Gagandeep
Singh, Gagandeep
Schotsaert, Michael
Mena, Ignacio
McCroskery, Stephen
Coughlan, Lynda
Krammer, Florian
García-Sastre, Adolfo
Palese, Peter
Sun, Weina
author_facet González-Domínguez, Irene
Martínez, Jose Luis
Slamanig, Stefan
Lemus, Nicholas
Liu, Yonghong
Lai, Tsoi Ying
Carreño, Juan Manuel
Singh, Gagandeep
Singh, Gagandeep
Schotsaert, Michael
Mena, Ignacio
McCroskery, Stephen
Coughlan, Lynda
Krammer, Florian
García-Sastre, Adolfo
Palese, Peter
Sun, Weina
author_sort González-Domínguez, Irene
collection PubMed
description Equitable access to vaccines is necessary to limit the global impact of the coronavirus disease 2019 (COVID-19) pandemic and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. In previous studies, we described the development of a low-cost vaccine based on a Newcastle Disease virus (NDV) expressing the prefusion-stabilized spike protein from SARS-CoV-2, named NDV-HXP-S. Here, we present the development of next-generation NDV-HXP-S variant vaccines, which express the stabilized spike protein of the Beta, Gamma, and Delta variants of concerns (VOC). Combinations of variant vaccines in bivalent, trivalent, and tetravalent formulations were tested for immunogenicity and protection in mice. We show that the trivalent preparation, composed of the ancestral Wuhan, Beta, and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant. IMPORTANCE This manuscript describes an extended work on the Newcastle disease virus (NDV)-based vaccine focusing on multivalent formulations of NDV vectors expressing different prefusion-stabilized versions of the spike proteins of different SARS-CoV-2 variants of concern (VOC). We demonstrate here that this low-cost NDV platform can be easily adapted to construct vaccines against SARS-CoV-2 variants. Importantly, we show that the trivalent preparation, composed of the ancestral Wuhan, Beta, and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant. We believe that these findings will help to guide efforts for pandemic preparedness against new variants in the future.
format Online
Article
Text
id pubmed-9241906
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-92419062022-06-30 Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice González-Domínguez, Irene Martínez, Jose Luis Slamanig, Stefan Lemus, Nicholas Liu, Yonghong Lai, Tsoi Ying Carreño, Juan Manuel Singh, Gagandeep Singh, Gagandeep Schotsaert, Michael Mena, Ignacio McCroskery, Stephen Coughlan, Lynda Krammer, Florian García-Sastre, Adolfo Palese, Peter Sun, Weina Microbiol Spectr Research Article Equitable access to vaccines is necessary to limit the global impact of the coronavirus disease 2019 (COVID-19) pandemic and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. In previous studies, we described the development of a low-cost vaccine based on a Newcastle Disease virus (NDV) expressing the prefusion-stabilized spike protein from SARS-CoV-2, named NDV-HXP-S. Here, we present the development of next-generation NDV-HXP-S variant vaccines, which express the stabilized spike protein of the Beta, Gamma, and Delta variants of concerns (VOC). Combinations of variant vaccines in bivalent, trivalent, and tetravalent formulations were tested for immunogenicity and protection in mice. We show that the trivalent preparation, composed of the ancestral Wuhan, Beta, and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant. IMPORTANCE This manuscript describes an extended work on the Newcastle disease virus (NDV)-based vaccine focusing on multivalent formulations of NDV vectors expressing different prefusion-stabilized versions of the spike proteins of different SARS-CoV-2 variants of concern (VOC). We demonstrate here that this low-cost NDV platform can be easily adapted to construct vaccines against SARS-CoV-2 variants. Importantly, we show that the trivalent preparation, composed of the ancestral Wuhan, Beta, and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant. We believe that these findings will help to guide efforts for pandemic preparedness against new variants in the future. American Society for Microbiology 2022-06-06 /pmc/articles/PMC9241906/ /pubmed/35658571 http://dx.doi.org/10.1128/spectrum.01538-22 Text en Copyright © 2022 González-Domínguez et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
González-Domínguez, Irene
Martínez, Jose Luis
Slamanig, Stefan
Lemus, Nicholas
Liu, Yonghong
Lai, Tsoi Ying
Carreño, Juan Manuel
Singh, Gagandeep
Singh, Gagandeep
Schotsaert, Michael
Mena, Ignacio
McCroskery, Stephen
Coughlan, Lynda
Krammer, Florian
García-Sastre, Adolfo
Palese, Peter
Sun, Weina
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
title Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
title_full Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
title_fullStr Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
title_full_unstemmed Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
title_short Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
title_sort trivalent ndv-hxp-s vaccine protects against phylogenetically distant sars-cov-2 variants of concern in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241906/
https://www.ncbi.nlm.nih.gov/pubmed/35658571
http://dx.doi.org/10.1128/spectrum.01538-22
work_keys_str_mv AT gonzalezdominguezirene trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT martinezjoseluis trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT slamanigstefan trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT lemusnicholas trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT liuyonghong trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT laitsoiying trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT carrenojuanmanuel trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT singhgagandeep trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT singhgagandeep trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT schotsaertmichael trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT menaignacio trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT mccroskerystephen trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT coughlanlynda trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT krammerflorian trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT garciasastreadolfo trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT palesepeter trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice
AT sunweina trivalentndvhxpsvaccineprotectsagainstphylogeneticallydistantsarscov2variantsofconcerninmice